Evidence map›Paper›PMID 36249172›Full record

ArticlePerspectives on behavior science2022

Revisiting an Analysis of Threats to Internal Validity in Multiple Baseline Designs.

Timothy A Slocum, P Raymond Joslyn, Beverly Nichols, Sarah E Pinkelman

Abstract read
In one paragraph

Article in Perspectives on behavior science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Timothy A SlocumUtah State University, 2865 Old Main Hill, Logan, UT 84322 USA.ORCID 0000-0002-4661-2403
P Raymond JoslynUtah State University, 2865 Old Main Hill, Logan, UT 84322 USA.ORCID https://orcid.org/0000-0002-8207-6505
Beverly NicholsUtah State University, 2865 Old Main Hill, Logan, UT 84322 USA.ORCID https://orcid.org/0000-0002-1021-4104
Sarah E PinkelmanUtah State University, 2865 Old Main Hill, Logan, UT 84322 USA.ORCID https://orcid.org/0000-0002-6380-6189

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In our previous article on threats to internal validity of multiple baseline design variations (Slocum et al., 2022), we argued that nonconcurrent multiple baseline designs (NCMB) are capable of rigorously demonstrating experimental control and should be considered equivalent to concurrent multiple baselines (CMB) in terms of internal validity. We were fortunate to receive five excellent commentaries on our article from experts in single-subject research design-four of whom endorsed the conclusion that NCMBs should be considered strong experimental designs capable of demonstrating experimental control. In the current article, we address the most salient points made in the five commentaries by further elaborating and clarifying the logic described in our original article. We address arguments related to classic threats including maturation, testing and session experience, and coincidental events (history). We rebut the notion that although NCMBs are strong, CMBs provide an increment of additional control and discuss the application of probability-based analysis of the likelihood of threats to internal validity. We conclude by emphasizing our agreement with many of the commentaries that selection of single-case experimental designs should be based on the myriad subtleties of research priorities and contextual factors rather than on a decontextualized hierarchy of designs.

Indexed as

ConcurrentInternal validityMultiple baseline designNonconcurrentResearch methodologySingle-case design

Identifiers

PMID36249172
PMCPMC9458797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.